Analysts Set Expectations for Edesa Biotech FY2029 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Analysts at Brookline Capital Markets issued their FY2029 earnings per share (EPS) estimates for shares of Edesa Biotech in a report released on Monday, June 29th. Brookline Capital Markets analyst K. Raja anticipates that the company will post earnings per share of ($1.87) for the year. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.57) per share. Brookline Capital Markets also issued estimates for Edesa Biotech’s FY2030 earnings at ($0.83) EPS.

Edesa Biotech (NASDAQ:EDSA) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.25).

Several other research analysts also recently commented on EDSA. Wall Street Zen upgraded Edesa Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Edesa Biotech in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $5.00.

Edesa Biotech Stock Up 6.0%

Edesa Biotech stock opened at $8.13 on Wednesday. The firm has a fifty day simple moving average of $9.49 and a two-hundred day simple moving average of $5.34. Edesa Biotech has a twelve month low of $0.72 and a twelve month high of $20.32. The company has a market capitalization of $72.28 million, a PE ratio of -6.07 and a beta of 1.03.

Hedge Funds Weigh In On Edesa Biotech

Several large investors have recently made changes to their positions in the business. Perceptive Advisors LLC purchased a new position in shares of Edesa Biotech during the first quarter valued at approximately $2,946,000. DRW Securities LLC bought a new position in Edesa Biotech during the 4th quarter valued at approximately $191,000. Diadema Partners LP purchased a new position in Edesa Biotech during the fourth quarter valued at $77,000. State Street Corp bought a new stake in Edesa Biotech in the fourth quarter worth $27,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Edesa Biotech in the third quarter worth $36,000. 5.50% of the stock is currently owned by hedge funds and other institutional investors.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.